NCT01389440已完成2 期
Phase II Study Open, Not Randomized to Evaluate the Efficacy and Safety of Neoadjuvant Treatment With Gemcitabine and Erlotinib Followed by Gemcitabine, Erlotinib and Radiotherapy in Patients With Resectable Pancreatic Adenocarcinoma
Grupo Espanol Multidisciplinario del Cancer Digestivo10 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2011年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 10
- 主要终点
- Percentage of ancients undergoing with neoadjuvant chemoradiotherapy and R0 resection
研究概览
简要总结
This is a Phase II open study, not randomized with a neoadjuvant therapy,combination of Gemcitabine (1,000 mg/m2/week) with Erlotinib (100mg/day) (3 cycles of 4 weeks), followed by gemcitabine (300 mg/m2/week) combined with Erlotinib (100mg/day) and radiotherapy (45 Gy / day fr180 cGy) (5 cycles of 1 week) in patients with resectable pancreatic adenocarcinoma to assess the percentage of R0 resections. They have planned a total of 21 visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to sign the inform consent form
- •Age between 18-75 years
- •Subject has not undergone any chemotherapy or radiotherapy previously
- •Functional status o-1 (ECOG scale)
- •Satisfy all radiological inclusion criteria (MSCT performed 28 days before the treatment starts and a centralized evaluation)
- •Patients with a cytologically confirmed diagnosis of pancreatic adenocarcinoma(preferably by EUS)
- •Appropriate analytical as inclusion criteria (7 days before the treatment starts):
- •bone marrow status: neutrophils ≥ 1,500x10^9/L; platelets ≥ 100x10^9/L; hemoglobin ≥ 9g/dL.
- •INR ≤ 1.5 and PTT ≤ 1.5 x upper range of normal.
- •Bilirubin ≤ 5 mg/dL
- •Albumin> 34 g/L
- •Renal function: creatinine ≤ 1.5 mg/dL and creatinine clearance> 50ml/min
排除标准
- •patients treated with any of the study's drugs
- •patients who has develop other primary tumors in 5 years prior to the inclusion at the clinical trial, except for cervix carcinoma in situ or basal cell skin cancer which have been treated properly.
- •significant clinical cardiovascular disease: stroke (≤ 6 months before the study inclusion), heart attack (≤ 6 months before inclusion), unstable ango pectoris, congestive heart failure second grade or higher of the New York Heart Association (NYHA) or serious cardiac arrhythmia requiring medication, uncontrolled hypertension
- •Total o partial bowel obstruction
- •Chronic diarrhea
- •Current treatment with another investigational drug or participation in another clinical trial within 30 days prior to inclusion.
- •Known hypersensitivity to any of the study drugs or their components
- •Currently o recent therapeutic treatment (opposite to prophylactic) with oral or parenteral anticoagulants (full dose) or thrombolytic agents. Patients who receive (or are candidates to receive) anticoagulants for prophylaxis of cardiovascular risk, should continue (or begin) treatment at baseline
- •Thromboembolic event history or bleeding in the 6 months prior to treatment.
- •Evidence of bleeding diathesis or coagulopathy.
- •Serious problems in wounds healing, ulcers or bone fractures.
- •Major surgery, open biopsy or significant traumatic injury 28 days before treatment.
- •Any other disease, metabolic disorder, physical examination findings or clinical laboratory that provides reasonable evidence for suspecting a disease or condition for which it is contraindicated or patient an experimental drug at high risk of experiencing complications related to treatment .
- •Patients undergoing with organ allografts requiring immunosuppressive treatment.
- •Pregnant or breastfeeding woman. It requires a negative pregnancy test (serum or urine) within 7 days before previous to treatment.
- •Men and women of childbearing potential (including women who have had their last menstrual period in less than 2 years) not using effective contraception precautions
- •Positive HIV status
- •Addiction to alcohol or other drugs
- •Known liver cirrhosis
研究组 & 干预措施
Gemcitabine, Erlotinib and radiotherapy
Experimental
Gemcitabine + Erlotinib follow by Gemcitabine + Erlotinib + radiotherapy
干预措施: Gemcitabine and Erlotinib (Drug)
结局指标
主要结局
Percentage of ancients undergoing with neoadjuvant chemoradiotherapy and R0 resection
时间窗: 3 years
次要结局
- To describe the safety of the treatment(3 years)
- Evaluate the response rate using RECIST criteria(3 years)
- Evaluate the percentage of resectability(3 years)
- Evaluate the percentage of lymphatic nodes removed(3 years)
- Evaluate the percentage of lymphatic nodes involved(3 years)
- Evaluate the pathological regression stage (primary tumor and lymphatic nodes)(3 years)
- Relate RECIST criteria with the pathological regress stage(3 years)
- Measure the progression free survival (time from the inclusion date to the progression of the disease or death)(3 years)
- Evaluate the overall survival time(3 years)
研究者
研究点 (10)
Loading locations...
相似试验
终止
2 期
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer PatientsMetastatic Pancreatic CancerNCT01461915Chimerix60
进行中（未招募）
1 期
Phase II, open label clinical study to investigate anti-tumour effect and tolerability of the PARP inhibitor 2X-121 in patients with metastatic breast cancer selected by the 2X-121 DRP®.MedDRA version: 20.0Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Metastatic Breast CancerEUCTR2017-003508-39-DKOncology Venture Aps26
终止
2 期
Comparing a new combination of medicines to the normal standard of care chemotherapy treatment given to patients who have been recently diagnosed with acute myeloid leukaemiaCancerISRCTN71474257DIDACT Foundation164
已完成
2 期
Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic CancerPancreatic NeoplasmsNCT00191568Eli Lilly and Company45
尚未招募
2 期
An Open clinical evaluation of siddha medicine pattai chooranam in leucorrhoeaCTRI/2020/09/028125Government Siddha Medical College